Skip to main content
Journal cover image

Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.

Publication ,  Journal Article
Cavazos, CM; Keir, ST; Yoshinari, T; Bigner, DD; Friedman, HS
Published in: Cancer Chemother Pharmacol
September 2001

PURPOSE: The in vivo antitumor activity of a novel topoisomerase I inhibitor, J-107088, was tested in athymic nude mice bearing subcutaneous or intracranial pediatric and adult malignant CNS tumor-derived xenografts. METHODS: J-107088 was administered to animals on days 1-5 and 8-12 via intraperitoneal injection at a dose of 54 mg/kg (162 mg/m2) per day in 10% dimethyl sulfoxide in 0.9% saline. The xenografts evaluated were derived from a childhood glioblastoma multiforme (D-456 MG), a childhood medulloblastoma (D-341 MED), an adult anaplastic astrocytoma (D-54 MG), an adult glioblastoma multiforme (D-245 MG), and a procarbazine-resistant subline of D-245 MG [D-245 MG (PR)]. RESULTS: J-107088 produced regressions and significant growth inhibition in all five of the xenograft lines growing subcutaneously. Growth delays ranged from 7.6 days with D-245 MG to 62.1 days with D-456 MG (P < 0.001). J-107088 also produced an 83% increase in survival in mice bearing intracranial D-456 MG (P < 0.001). CONCLUSION: These results indicate that J-107088 may be active in the treatment of childhood and adult malignant brain tumors and provide the rationale for initiation of clinical trials with this agent.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

September 2001

Volume

48

Issue

3

Start / End Page

250 / 254

Location

Germany

Related Subject Headings

  • Tumor Cells, Cultured
  • Treatment Outcome
  • Transplantation, Heterologous
  • Topoisomerase I Inhibitors
  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, Nude
  • Mice
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cavazos, C. M., S. T. Keir, T. Yoshinari, D. D. Bigner, and H. S. Friedman. “Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.Cancer Chemother Pharmacol 48, no. 3 (September 2001): 250–54. https://doi.org/10.1007/s002800100347.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

September 2001

Volume

48

Issue

3

Start / End Page

250 / 254

Location

Germany

Related Subject Headings

  • Tumor Cells, Cultured
  • Treatment Outcome
  • Transplantation, Heterologous
  • Topoisomerase I Inhibitors
  • Survival Rate
  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, Nude
  • Mice
  • Male